Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Anaxomics Biotech
Frontiers | In silico evaluation of the role of lisdexamfetamine on attention-deficit/hyperactivity disorder common psychiatric comorbidities: mechanistic insights on binge eating disorder and depression
In silico evaluation of the role of lisdexamfetamine on attention-deficit/hyperactivity disorder common psychiatric comorbidities: mechanistic insights on binge eating disorder and depression 1Unidad Ambulatoria de Psiquiatría y Salud Mental de la Infancia, Niñez y Adolescencia. Hospital Perpetuo Socorro., Spain 2Anaxomics Biotech, Spain 3Research Programme on Biomedical Informatics (GRIB), Departament de Ciències Experimentals i de la Salut, Universitat Pompeu Fabra, Spain 4Medical Department.
Frontiers | In silico clinical trial evaluating lisdexamfetamine’s and methylphenidate’s mechanism of action computational models in an attention-deficit/hyperactivity disorder virtual patients’ population
1. Introduction Attention-deficit/hyperactivity disorder (ADHD) is a psychiatric condition well recognized in the pediatric population in which children suffer from persistent inattentiveness, hyperactivity, impulsivity, or any combination thereof (1). ADHD global prevalence in school-age children is estimated at around 7.2% (2) and is generally accepted to range from 6 to 10% (3).
Artificial intelligence assessment of the potential of tocilizumab along with corticosteroids therapy for the management of COVID-19 evoked acute respiratory distress syndrome
3.3 Combination mechanisms of tocilizumab plus dexamethasone in the management of COVID-19 evoked ARDS The predicted MoA for each drug were jointly evaluated, aiming at the elucidation of the likely pharmacological mechanisms evoked by the combination against COVID-19 evoked ARDS (Fig 5). Fig 5. Mechanism of action of dexamethasone and tocilizumab as combined therapy.
Unveiling chronic spontaneous urticaria pathophysiology through systems biology
Article Info Publication History Accepted: December 20, 2022 Received in revised form: December 6, 2022 Received: July 15, 2022 Publication stage In Press Journal Pre-Proof Footnotes Conflict of interest MF has received honoraria (advisory board, speaker) from Genentech, Menarini, Uriach, FAES, and MSD; has received a Research Grant from GSK and Novartis; and advisory and speaker fees from Novartis. Non-Financial Interests: fellow of the AAAAI.
In-silico drug repurposing study predicts the combination of pirfenidone and melatonin as a promising candidate therapy to reduce SARS-CoV-2 infection progression and respiratory distress caused by cytokine storm
Loading metrics Open Access Peer-reviewed Research Article Laura Artigas, Mireia Coma , Pedro Matos-Filipe, Joaquim Aguirre-Plans, Judith Farrés, Raquel Valls, Narcis Fernandez-Fuentes, Juan de la Haba-Rodriguez, Alex Olvera, Jose Barbera, Rafael Morales, Baldo Oliva , Jose Manuel Mas Laura Artigas, Mireia Coma, Pedro Matos-Filipe, Joaquim Aguirre-Plans, Judith Farrés, Raquel Valls, Narcis Fernandez-Fuentes, Juan de la Haba-Rodriguez, Alex Olvera, Jose Barbera Published: October 2, 2020...
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Anaxomics
Contact Anaxomics, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack